檢索結果 - Haihua Zheng
- Showing 1 - 3 results of 3
-
1
-
2
Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indo... 由 John F. Gerecitano, Haihua Zheng, Lidia Mongay Soler, Rodrigo Ito, Diego Reis, Chih-Ming Lu, Jiayu Shen, Barrett H. Childs, Pier Luigi Zinzani
出版 2017Artigo -
3
SAFETY RUN‐IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN'S LYMPHOMA 由 John F. Gerecitano, Armando Santoro, Sirpa Leppä, T. Kim, W. Kim, Ann Janssens, Michael Pedersen, Diego Reis, Camille Granvil, Jiayu Shen, Haihua Zheng, Barrett H. Childs, Pier Luigi Zinzani
出版 2017Artigo
相關主題
Internal medicine
Medicine
Bendamustine
Follicular lymphoma
Gastroenterology
Lymphoma
Ofatumumab
Oncology
Rituximab
Adverse effect
Angiogenesis
Basic fibroblast growth factor
Biology
Cancer research
Cell biology
Chemotherapy
Chemotherapy regimen
Chronic lymphocytic leukemia
Corneal neovascularization
Fibroblast growth factor
Growth factor
Ibrutinib
Idelalisib
Immunology
Leukemia
Neovascularization
Obinutuzumab
Phases of clinical research
Receptor
Regimen